
By Cindy Shmerler from NYT Health https://ift.tt/3Rn1HkT

Some with cognitive decline may still be safe to drive. But impairment often gets worse, and at some point, these difficult conversations will be needed.
Study results show semaglutide for weight loss (Wegovy) cut problems in the heart and blood vessels in a 17,000-person trial, which should reframe the health benefit of this weight loss drug.
Identifying specific genes adds to growing evidence that biology, in part, drives obesity. Researchers hope the findings will lead to effective treatments.
